Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MODN
376
DELISTED
MODEL N, INC.
MODN
| $74M | 0.06% |
2,109,144
+395,544
| +23% | +$12M |
|
377
Polaris
PII
$3.89B
| $73.8M | 0.06% |
725,618
+461,218
| +174% | +$44.8M |
|
378
Match Group
MTCH
$8.37B
| $73.6M | 0.06% |
896,151
-1,107,349
| -55% | -$80.5M |
|
379
Brown & Brown
BRO
$23.6B
| $73.5M | 0.06% |
1,862,557
-780,643
| -30% | -$29.3M |
|
380
Workiva
WK
$3.7B
| $73.4M | 0.06% |
1,746,600
-149,000
| -8% | -$6.28M |
|
381
National Health Investors
NHI
$3.48B
| $73.3M | 0.06% |
899,100
-14,400
| -2% | -$1.18M |
|
|
WBC
382
DELISTED
WABCO HOLDINGS INC.
WBC
| $73.2M | 0.06% |
539,900
+270,300
| +100% | +$36.4M |
|
383
Helmerich & Payne
HP
$4.23B
| $72.9M | 0.06% |
1,603,700
+792,600
| +98% | +$31.8M |
|
384
NVR
NVR
$16.7B
| $72.6M | 0.06% |
19,070
-14,690
| -44% | -$54.4M |
|
385
InterDigital
IDCC
$8.9B
| $72.5M | 0.06% |
1,331,267
+112,200
| +9% | +$6.2M |
|
|
AVTA
386
DELISTED
Avantax, Inc. Common Stock
AVTA
| $72.5M | 0.06% |
2,773,300
+4,900
| +0.2% | +$110K |
|
387
Regency Centers
REG
$13.9B
| $72.4M | 0.06% |
1,147,126
-592,564
| -34% | -$38.9M |
|
388
Yum China
YUMC
$16.3B
| $72M | 0.06% |
1,499,790
+115,390
| +8% | +$5.13M |
|
389
Applied Materials
AMAT
$435B
| $71.6M | 0.06% |
+1,172,969
| New | +$65.9M |
|
390
Nucor
NUE
$61.6B
| $71.4M | 0.05% |
1,268,652
+417,799
| +49% | +$22.8M |
|
391
Assurant
AIZ
$13.9B
| $71M | 0.05% |
541,290
-522,110
| -49% | -$67.2M |
|
392
Intuitive Surgical
ISRG
$141B
| $70.8M | 0.05% |
+359,130
| New | +$67.2M |
|
|
DISH
393
DELISTED
DISH Network Corp.
DISH
| $70.5M | 0.05% |
1,986,459
-20,242
| -1% | -$701K |
|
394
WD-40
WDFC
$3.11B
| $70.1M | 0.05% |
361,123
-30,100
| -8% | -$5.67M |
|
395
Dine Brands
DIN
$448M
| $69.9M | 0.05% |
837,200
-7,300
| -0.9% | -$567K |
|
|
DEA
396
Easterly Government Properties
DEA
$1.15B
| $69.6M | 0.05% |
1,173,152
+269,237
| +30% | +$15.2M |
|
397
Dr. Reddy's Laboratories
RDY
$10.3B
| $69.3M | 0.05% |
8,544,410
+1,152,000
| +16% | +$9.1M |
|
|
PGRE
398
DELISTED
Paramount Group
PGRE
| $69.2M | 0.05% |
4,970,899
-898,100
| -15% | -$12.1M |
|
399
Onto Innovation
ONTO
$20.6B
| $69M | 0.05% |
1,888,878
+759,778
| +67% | +$25.8M |
|
400
Colliers International
CIGI
$5.19B
| $69M | 0.05% |
884,500
+40,400
| +5% | +$2.91M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.